Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.
Fabian AckerJörg ChromikEmily TiedjenSebastian WolfJonas B VischedykPhilipp MakowkaJulius C EnssleKhouloud KouidriMartin SebastianBjörn SteffenThomas OellerichHubert ServeAndreas NeubauerJonas A SchäferJörg T BittenbringPublished in: European journal of haematology (2024)
These data align with findings from the pivotal VIALE-A trial and support the use of HMA-VEN in patients unfit for intensive therapy.